Table 1.
Baseline patient characteristics.
| Pembrolizumab group (n = 49) | Bevacizumab group (n = 53) | P-value | |
|---|---|---|---|
| Age, years, median (IQR) | 64 (59-67) | 60 (50-65) | 0.005 |
| <65 | 27 (55.1%) | 39 (73.6%) | |
| ≥65 | 22 (44.9%) | 14 (26.4%) | |
| Sex | 0.475 | ||
| male | 39 (79.6%) | 39 (73.6%) | |
| female | 10 (20.4%) | 14 (26.4%) | |
| Smoking history | 0.002 | ||
| Never | 12 (24.5%) | 29 (54.7%) | |
| Previous or current | 37 (75.5%) | 24 (45.3%) | |
| ECOG PS | 0.669 | ||
| 0 | 3 (6.1%) | 2 (3.8%) | |
| 1 | 46 (93.9%) | 51 (96.2%) | |
| Tumor histology | 0.607 | ||
| Adenocarcinoma | 47 (95.9%) | 52 (98.1%) | |
| Others | 2 (4.1%) | 1 (1.9%) | |
| Stage | 0.182 | ||
| IIIB~IIIC | 4 (8.2%) | 9 (17.0%) | |
| IV | 45 (91.8%) | 44 (83.0%) | |
| Number of metastatic sites | 0.001 | ||
| 0 | 4 (8.2%) | 9 (17.0%) | |
| 1-2 | 24 (49.0%) | 38 (71.7%) | |
| ≥3 | 21 (42.9%) | 6 (11.3%) | |
| Metastatic site | |||
| Bone | 25 (51.0%) | 16 (30.2%) | 0.032 |
| Brain | 10 (20.4%) | 7 (13.2%) | 0.330 |
| Liver | 5 (10.2%) | 2 (3.8%) | 0.256 |
| Chest | 40 (81.6%) | 38 (71.7%) | 0.237 |
| Adrenal gland | 13 (26.5%) | 7 (13.2%) | 0.090 |
| Hematologic parameters, median (IQR) | |||
| LDH, U/L | 193 (144.50-260.00) | 198 (170-229) | 0.492 |
| NLR | 3.20 (2.35-5.77) | 2.49 (1.99-4.21) | 0.107 |
| dNLR | 2.19 (1.73-3.13) | 1.92 (1.49-2.55) | 0.098 |
| PLR | 149.26 (121.62-196.62) | 138.08 (97.13-214.66) | 0.177 |
| LMR | 2.96 (2.17-3.78) | 3.50 (2.30-4.73) | 0.252 |
| AEC, ×109/L | 0.11 (0.05-0.23) | 0.16 (0.09-0.26) | 0.181 |
| PD-L1 TPS | <0.001 | ||
| <1% | 9 (18.4%) | 8 (15.1%) | |
| 1%-49% | 9 (18.4%) | 1 (1.9%) | |
| >50% | 13 (26.5%) | 3 (5.7%) | |
| unknown | 18 (36.7%) | 41 (77.4%) | |
| Pembrolizumab/Bevacizumab exposure, doses | 0.636 | ||
| 0 to ≤6 | 21 (42.9%) | 21 (39.6%) | |
| >6 to ≤12 | 17 (34.7%) | 22 (41.5%) | |
| >12 to ≤18 | 7 (14.3%) | 4 (7.5%) | |
| >18 | 4 (8.2%) | 6 (11.3%) | |
| Radiotherapy combination | 0.118 | ||
| Yes | 10 (20.4%) | 5 (9.4%) | |
| No | 39 (79.6%) | 48 (90.6%) |
IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance-status; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AEC, absolute eosinophil count; PD-L1 TPS, programmed death-1 tumor proportion score.
Some percentages may not sum to 100% because of rounding.